1. 1-(2-Hydroxyethyl)-2-imidazolidinone, a heparanase and matrix metalloproteinase inhibitor, improves epidermal basement membrane structure and epidermal barrier function.
- Author
-
Iriyama S, Yamanishi H, Kunizawa N, Hirao T, and Amano S
- Subjects
- Adult, Basement Membrane drug effects, Cell Differentiation, Cell Proliferation, DNA Damage, Dermis drug effects, Humans, Japan, Male, Matrix Metalloproteinase 9 metabolism, Middle Aged, Skin pathology, Ultraviolet Rays, Basement Membrane metabolism, Epidermis metabolism, Glucuronidase antagonists & inhibitors, Imidazolidines pharmacology, Matrix Metalloproteinase Inhibitors pharmacology, Skin drug effects
- Abstract
Daily exposure to sunlight is known to affect the structure and function of the epidermal basement membrane (BM), as well as epidermal differentiation and epidermal barrier function. The aim of this study is to clarify whether the inhibition of BM-degrading enzymes such as heparanase and matrix metalloproteinase 9 (MMP-9) can improve the epidermal barrier function of facial skin, which is exposed to the sun on a daily basis. 1-(2-hydroxyethyl)-2-imidazolidinone (HEI) was synthesized as an inhibitor of both heparanase and MMP-9. HEI inhibited not only the BM damage at the DEJ but also epidermal proliferation, differentiation, water contents and transepidermal water loss abnormalities resulting from ultraviolet B (UVB). This was determined in this study by the use of UVB-induced human cultured skins as compared with the control without HEI. Moreover, topical application of HEI improved epidermal barrier function by increasing water content and decreasing transepidermal water loss in daily sun-exposed facial skin as compared with non-treated skins. These results suggest that the inhibition of both heparanase and MMP-9 is an effective way to care for regularly sun-exposed facial skin by protecting the BM from damage., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF